³í¹®) Serial circulating-tumor DNA analysis with a tumor naïve next-generation sequencing panel detects minimal residual disease and predicts outcome in ovarian cancer ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ Áø´Ü°Ë»çÀÇÇб³½Ç À̽ÂÅ ±³¼ö, ¿¬¼¼¾Ïº´¿ø ºÎÀξϼ¾ÅÍ ÀÌÁ¤À± ±³¼ö, ±èÀ¯³ª °»ç, ±¹¹Î°Ç°º¸Çè Àϻ꺴¿ø Áø´Ü°Ë»çÀÇÇаú ÇãÁøÈ£ ÀüÀÓÀÇ ¿¬±¸ÆÀ